XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue        
Total revenues $ 51,812 $ 32,868 $ 124,321 $ 103,213
Royalties        
Disaggregation of Revenue        
Total revenues 31,709 23,888 73,966 62,473
Revenue from intangible royalty assets        
Disaggregation of Revenue        
Total revenues 26,552 23,863 67,512 61,447
Kyprolis        
Disaggregation of Revenue        
Total revenues 11,599 10,537 27,229 24,862
Evomela        
Disaggregation of Revenue        
Total revenues 1,747 2,497 5,877 7,404
Teriparatide injection        
Disaggregation of Revenue        
Total revenues 2,376 2,800 6,520 9,913
Rylaze        
Disaggregation of Revenue        
Total revenues 3,886 3,678 10,070 9,315
Filspari        
Disaggregation of Revenue        
Total revenues 3,206 1,122 7,402 1,707
Vaxneuvance        
Disaggregation of Revenue        
Total revenues 1,466 1,313 3,962 2,990
Other        
Disaggregation of Revenue        
Total revenues 2,272 1,916 6,452 5,256
Income from financial royalty assets        
Disaggregation of Revenue        
Total revenues 5,157 25 6,454 1,026
Captisol        
Disaggregation of Revenue        
Total revenues 6,255 8,608 22,967 24,450
Contract revenue and other income        
Disaggregation of Revenue        
Total revenues 13,848 372 27,388 16,290
Milestone and other        
Disaggregation of Revenue        
Total revenues 13,848 372 25,444 16,290
Other income        
Disaggregation of Revenue        
Total revenues $ 0 $ 0 $ 1,944 $ 0